You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. RFA-DA-22-021: Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R41/R42- Clinical Trial Not Allowed)

    Release Date: 04-08-2021Open Date: 07-10-2021Due Date: 08-10-2021Close Date: 08-11-2021

    Background SUDs are a set of complex and chronic diseases with an interplay between genetic and environmental factors. In the constellation of SUDs, the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM V) provides a framework that includes ten separate classes of substances and covers 11 different criteria for their diagnosis. Currently, there are a limited number of phar ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. PA-18-709: Novel Tools for Investigating Brain-derived GPCRs in Mental Health Research (R41/R42 Clinical Trial Not Allowed)

    Release Date: 03-15-2018Open Date: 08-05-2018 Due Dates: Multiple Close Date: 09-05-2021

    Background G-protein coupled receptor proteins (GPCRs) are membrane bound proteins that serve to modulate cellular activities. Many of the GPCRs have potential significance in healthy mental function and in mental disorders, including receptors for most neurotransmitters and neuropeptides. Drugs targeting GPCRs are currently used in the treatment of mental disorders such as schizophrenia, anxie ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  3. PA-18-927 : Innovative Technologies for HIV Behavioral and Social Science Research (R41/R42 Clinical Trial Optional)

    Release Date: 09-19-2018Open Date: 12-05-2018 Due Dates: Multiple Close Date: 09-05-2021

    Background Technology-enabled HIV research has emerged in the past decade as a dynamic field that offers potential to bring HIV prevention and treatment efforts to scale. Technological innovations can help to reach vulnerable and at-risk populations such as minorities, adolescents, older adults, and individuals from rural settings who have challenges accessing conventional prevention and treatmen ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. PA-19-021: Advancing Imaging, Device Production, and Clinical Capabilities in Digital Dentistry (R41/R42 Clinical Trial Not Allowed)

    Release Date: 10-10-2018Open Date: 12-05-2018 Due Dates: Multiple Close Date: 09-05-2021

    Purpose Digital dentistry uses advanced materials and powerful manufacturing technologies aided by 3D imaging and processing software algorithms to produce dental devices and perform complex dental procedures. This Funding Opportunity Announcement (FOA) encourages innovation, optimization and customization of core technologies in digital dentistry that improve efficiency of oral healthcare delive ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  5. PA-19-033 : Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R41/R42 Clinical Trial Not Allowed)

    Release Date: 10-24-2018Open Date: 12-05-2018 Due Dates: Multiple Close Date: 09-05-2021

    Background The human genome has revealed a great deal about the human proteome, though significant portions remain understudied. Only a subset of expressed proteins demonstrates the requisite properties to serve as targets for the development of therapeutics. Many bona fide drug targets likely remain to be discovered in the "Druggable Genome" (DG), which can be defined as a subset of the ~20,000 ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  6. RFA-DA-19-020 : HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R41/R42- Clinical Trial Optional)

    Release Date: 12-10-2018Open Date: 12-10-2018 Due Dates: Multiple Close Date: 09-08-2021

    The National Center for Advancing Translational Sciences (NCATS) will not accept primary assignment to applications proposing clinical trial(s) under this funding announcement. Please direct any questions to the NCATS scientific contact. Purpose More than 2 million individuals in the United States have an opioid use disorder (OUD), most starting with opioid analgesics prescribed to them or procu ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. RFA-AG-22-014: NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R41/R42 Clinical Trial Optional)

    Release Date: 06-10-2021Open Date: 09-26-2021Due Date: 10-26-2021Close Date: 10-27-2021

    The number of available tenure-track faculty positions has not kept pace with the growing number of Ph.D. graduates in recent years. This imbalance has created a very competitive job environment, making it increasingly difficult for Ph.D. graduates to transition to academic appointments. Doctoral and post-doctoral training programs have heavily revolved around developing skill sets that are direct ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  8. DARPA BAA: Various Topics with Varying Open and Close Dates- See Description for Links

    Release Date: 12-17-2020Open Date: 01-01-2021Due Date: 12-31-2021Close Date: 12-31-2021

    This topic is released under a DoD Component Annual BAA. Annual BAA topics are released throughout the year with varying open and close dates. Please visit https://www.dodsbirsttr.mil/topics-app/ and https://rt.cto.mil/rtl-small-business-resources/sbir-sttr/ for specific topic open and close dates as well as BAA documents and instructions.”

    STTRPhase IDepartment of DefenseDefense Advanced Research Projects Agency
  9. SDA BAA: Various Topics with Varying Open and Close Dates- See Description for Links

    Release Date: 12-02-2020Open Date: 01-01-2021Due Date: 12-31-2021Close Date: 12-31-2021

    This topic is released under a DoD Component Annual BAA. Annual BAA topics are released throughout the year with varying open and close dates. Please visit https://www.dodsbirsttr.mil/topics-app/ and https://rt.cto.mil/rtl-small-business-resources/sbir-sttr/ for specific topic open and close dates as well as BAA documents and instructions.”

    STTRPhase IDepartment of DefenseSpace Development Agency
  10. PA-19-075 : Enabling Technologies to Accelerate Development of Oral Biodevices (R41/R42 Clinical Trial Not Allowed)

    Release Date: 11-26-2018Open Date: 03-05-2019 Due Dates: Multiple Close Date: 01-05-2022

    Purpose This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government